Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 1/20 | 0.71 |
| ▸ | CXCL12 | P48061 | 5/20 | 0.69 |
| ▸ | MAOB | P27338 | 9/20 | 0.66 |
| ▸ | MAOA | P21397 | 4/20 | 0.64 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.63 |
| ▸ | DHODH | Q02127 | 1/20 | 0.62 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.61 |
| ▸ | GPR183 | P32249 | 1/20 | 0.60 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30382766 | 1.00 | PTGS2 (0.71) | PTGS2CXCL12MAOBMAOACYP1B1 | |
| SCHEMBL1225523 | 1.00 | PTGS2 (0.71) | PTGS2CXCL12MAOBMAOACYP1B1 | |
| SCHEMBL30383198 | 0.89 | PTGS2 (0.69) | PTGS2CXCL12MAOBMAOACYP1B1 | |
| SCHEMBL4258938 | 0.89 | PTGS2 (0.69) | PTGS2CXCL12MAOBCYP1B1DHODH | |
| SCHEMBL31233368 | 0.89 | PTGS2 (0.69) | PTGS2CXCL12MAOBMAOACYP1B1 | |
| SCHEMBL25199743 | 0.89 | PTGS2 (0.69) | PTGS2CXCL12MAOBMAOACYP1B1 | |
| SCHEMBL4258940 | 0.89 | PTGS2 (0.69) | PTGS2CXCL12MAOBCYP1B1DHODH | |
| SCHEMBL7308126 | 0.89 | PTGS2 (0.69) | PTGS2CXCL12MAOBMAOACYP1B1 | |
| SCHEMBL7304255 | 0.89 | PTGS2 (0.69) | PTGS2CXCL12MAOBMAOACYP1B1 | |
| SCHEMBL13869118 | 0.87 | PTGS2 (0.72) | PTGS2CXCL12MAOBMAOACYP1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110230407-A1 | HEPATOCYTE GROWTH FACTOR PATHWAY ACTIVATORS IN DEMYELINATING DISEASES AND CENTRAL NERVOUS SYSTEM TRAUMA | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2011-09-22 | — | — | US | claimed |
| US-20030216459-A1 | Small-molecule modulators of hepatocyte growth factor / scatter factor activities | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH | 2003-11-20 | — | — | US | claimed |
| US-6589997-B2 | 1-Phenylprop-2-en-1-one derivatives as wound healing, anticarcinogenic, antiarthritic, antitumor, antiproliferative, antiinflammatory or antimetastasis agents | NORTH SHORE-LONG ISLAND JEWISH HEALTH SYSTEM | 2003-07-08 | — | — | US | claimed |
| US-20030045559-A1 | Small-molecule modulators of hepatocyte growth factor / scatter factor activities | NORTH SHORE-LONG ISLAND JEWISH HEALTH SYSTEM | 2003-03-06 | — | — | US | claimed |
| US-11044909-B2 | Composition for destruction of microalgae or sphaerocarpus | CUREARTH, INC. (KR) | 2021-06-29 | — | — | US | disclosed |
| US-20180271091-A1 | COMPOSITION FOR DESTRUCTION OF MICROALGAE OR SPHAEROCARPUS | CUREARTH, INC. (KR) | 2018-09-27 | — | — | US | disclosed |
| EP-3363288-A1 | COMPOSITION FOR DESTRUCTION OF MICROALGAE OR SPHAEROCARPUS | Curearth, Inc. (KR) | 2018-08-22 | — | — | EP | disclosed |
| US-8193177-B2 | Hepatocyte growth factor pathway activators in fibrotic connective tissue diseases | ANGION BIOMEDICA CORP. (US) | 2012-06-05 | — | — | US | disclosed |
| US-20110230407-A1 | HEPATOCYTE GROWTH FACTOR PATHWAY ACTIVATORS IN DEMYELINATING DISEASES AND CENTRAL NERVOUS SYSTEM TRAUMA | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2011-09-22 | — | — | US | disclosed |
| US-7879898-B1 | treating a chronic obstructive pulmonary disease using modulators of HGF/SF activity; for example, 3-(5-chloro-1,3-dimethyl-1H-pyrazol-4-yl)-1-(4-chlorophenyl)prop-2-en-1-one; emphysema | ANGION BIOMEDICA CORP. (US) | 2011-02-01 | — | — | US | disclosed |
| US-20100256117-A1 | HEPATOCYTE GROWTH FACTOR PATHWAY ACTIVATORS IN FIBROTIC CONNECTIVE TISSUE DISEASES | ANGION BIOMEDICA CORP. | 2010-10-07 | — | — | US | disclosed |
| WO-2009064422-A2 | HEPATOCYTE GROWTH FACTOR PATHWAY ACTIVATORS IN FIBROTIC CONNECTIVE TISSUE DISEASES | ANGION BIOMEDICA CORP. (US) | 2009-05-22 | — | — | WO | disclosed |
| US-20050096372-A1 | Small-molecule modulators of hepatocyte growth factor/scatter factor activities | PILLARISETTI SIVARAM (US) | 2005-05-05 | — | — | US | disclosed |
| US-6855728-B2 | Small-molecule modulators of hepatocyte growth factor / scatter factor activities | NORTH SHORE-LONG ISLAND JEWISH HEALTH SYSTEM (US) | 2005-02-15 | — | — | US | disclosed |
| US-20030216459-A1 | Small-molecule modulators of hepatocyte growth factor / scatter factor activities | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH | 2003-11-20 | — | — | US | disclosed |
| EP-1355921-A2 | MODULATORS OF CELLULAR PROLIFERATION AND ANGIOGENESIS, METHODS FOR USE AND IDENTIFICATION THEREOF | North Shore-Long Island Jewish Health System (US) | 2003-10-29 | — | — | EP | disclosed |
| WO-2002002593-A2 | MODULATORS OF CELLULAR PROLIFERATION AND ANGIOGENESIS, METHODS FOR USE AND IDENTIFICATION THEREOF | NORTH SHORE-LONG ISLAND JEWISH HEALTH SYSTEM (US) | 2002-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230407-A1 | HEPATOCYTE GROWTH FACTOR PATHWAY ACTIVATORS IN DEMYELINATING DISEASES AND CENTRAL NERVOUS SYSTEM TRAUMA | HGF, HGFAC, HDGF | PTGS2 3307/4885CXCL12 61/4885MAOB 4296/4885 |
| US-20030045559-A1 | Small-molecule modulators of hepatocyte growth factor / scatter factor activities | HGF, HDGF, MET | PTGS2 361/4885CXCL12 66/4885MAOB 3085/4885 |
| US-20030216459-A1 | Small-molecule modulators of hepatocyte growth factor / scatter factor activities | HGF, HDGF, MET | PTGS2 361/4885CXCL12 66/4885MAOB 3085/4885 |
| US-20050096372-A1 | Small-molecule modulators of hepatocyte growth factor/scatter factor activities | HGF, HDGF, MET | PTGS2 361/4885CXCL12 66/4885MAOB 3085/4885 |
| US-20100256117-A1 | HEPATOCYTE GROWTH FACTOR PATHWAY ACTIVATORS IN FIBROTIC CONNECTIVE TISSUE DISEASES | HGF, HDGF, HGFAC | PTGS2 1483/4885CXCL12 89/4885MAOB 3466/4885 |
| US-20180271091-A1 | COMPOSITION FOR DESTRUCTION OF MICROALGAE OR SPHAEROCARPUS | TK1, TRHDE, TK2 | PTGS2 1856/4885CXCL12 3290/4885MAOB 3382/4885 |
| US-11044909-B2 | Composition for destruction of microalgae or sphaerocarpus | TK1, TRHDE, TK2 | PTGS2 1856/4885CXCL12 3290/4885MAOB 3382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.